Status:
COMPLETED
Opsin Receptors in Melasma
Lead Sponsor:
Universidad Autonoma de San Luis Potosí
Collaborating Sponsors:
Hospital Central "Dr. Ignacio Morones Prieto"
Conditions:
Melasma
Eligibility:
FEMALE
18-60 years
Phase:
NA
Brief Summary
Melasma is a hyperpigmentation disorder that is probably exacerbated by visible light. Opsin receptors (OPN 1, 2, 3, 4 y 5) were described in the skin, being capable of activating melanogenesis induce...
Eligibility Criteria
Inclusion
- Patients diagnosed with melasma, of 18 years of age and older, without previous treatment or photoprotection measures within the previous 4 weeks, who had Melasma Activity and Severity Index (MASI) scores higher than 7
Exclusion
- pregnancy or nursing, menopause, coexistence of other pigmentation conditions, heat exposure, regular exercise, diet restriction, consumption of food supplements or any type of drugs (including anti-inflammatories and hormonal treatments) within the previous 2 months, and women who had given birth within 1 year
Key Trial Info
Start Date :
January 31 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 15 2019
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT04417348
Start Date
January 31 2019
End Date
December 15 2019
Last Update
June 4 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dermatology Department. Hospital Central "Dr. Ignacio Morones Prieto"
San Luis Potosí City, Mexico, 78290